Utilisation trend of long-acting insulin analogues including biosimilars across Europe: findings and implications
| العنوان: | Utilisation trend of long-acting insulin analogues including biosimilars across Europe: findings and implications |
|---|---|
| المؤلفون: | Mikael Hoffmann, Stuart McTaggart, Vanda Marković-Peković, Irene Langner, Skule Ingeberg, Iva Selke Krulichová, Carol Holmes, Juraj Slabý, Brian Godman, Biljana Tubić, Svens Henkuzens, Corinne Zara, Jakub Rutkowski, Jurij Fürst, András Inotai, Stephen Campbell, Konstantin Tachkov, Sean MacBride-Stewart, Ileana Mardare, Mihajlo Jakovljevic, Kristina Garuolienė, Marta Turu Pedrola, Øyvind Melien, Gisbert Selke, Magdalene Wladysiuk, Björn Wettermark, Amanj Kurdi, Arianit Jakupi, Caridad Pontes, Vasileios Kourafalos, Manfred Hinteregger, Eleonora Allocati, Radka Nejezchlebova, Guenka Petrova, Francis Kalemeera, Rita Banzi, András Harsányi, Patricia Vella Bonanno, Ott Laius, Robert Sauermann, Alice Pisana, Jolanta Gulbinovič, Anna Nachtnebel, Iris Hoxha |
| المصدر: | BioMed research international, London : Hindawi Ltd., 2021, vol. 2021, art. no. 9996193, p. [1-16] BioMed Research International BioMed Research International, Vol 2021 (2021) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi, Article Subject, Long acting insulin, Cost-Benefit Analysis, Health authority, medicine.medical_treatment, Pharmaceutical policy, Insulin Glargine, Genetics and Molecular Biology, General Biochemistry, Genetics and Molecular Biology, Patient Education as Topic, Systematic reviews (Medical research), Diabetes Mellitus, medicine, Humans, Hypoglycemic Agents, Poor glycaemic control, Drugs -- Costs, Biosimilar Pharmaceuticals, General Immunology and Microbiology, Public economics, Insulin glargine, Insulin, Stakeholder, Biosimilar, Health Care Service and Management, Health Policy and Services and Health Economy, General Medicine, Europe, Insulin, Long-Acting, Eastern european, Diabetes -- Patients -- Europe, General Biochemistry, Medicine, Business, Research Article, medicine.drug |
| الوصف: | Background. Diabetes mellitus rates and associated costs continue to rise across Europe enhancing health authority focus on its management. The risk of complications is enhanced by poor glycaemic control, with long-acting insulin analogues developed to reduce hypoglycaemia and improve patient convenience. There are concerns though with their considerably higher costs, but moderated by reductions in complications and associated costs. Biosimilars can help further reduce costs. However, to date, price reductions for biosimilar insulin glargine appear limited. In addition, the originator company has switched promotional efforts to more concentrated patented formulations to reduce the impact of biosimilars. There are also concerns with different devices between the manufacturers. As a result, there is a need to assess current utilisation rates for insulins, especially long-acting insulin analogues and biosimilars, and the rationale for patterns seen, among multiple European countries to provide future direction. Methodology. Health authority databases are examined to assess utilisation and expenditure patterns for insulins, including biosimilar insulin glargine. Explanations for patterns seen were provided by senior-level personnel. Results. Typically increasing use of long-acting insulin analogues across Europe including both Western and Central and Eastern European countries reflects perceived patient benefits despite higher prices. However, activities by the originator company to switch patients to more concentrated insulin glargine coupled with lowering prices towards biosimilars have limited biosimilar uptake, with biosimilars not currently launched in a minority of European countries. A number of activities were identified to address this. Enhancing the attractiveness of the biosimilar insulin market is essential to encourage other biosimilar manufacturers to enter the market as more long-acting insulin analogues lose their patents to benefit all key stakeholder groups. Conclusions. There are concerns with the availability and use of insulin glargine biosimilars among European countries despite lower costs. This can be addressed. peer-reviewed |
| وصف الملف: | application/pdf; text/xhtml |
| اللغة: | English |
| تدمد: | 2314-6133 2314-6141 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f71eb049d04b088f4f63846e1ca06c https://repository.vu.lt/VU:ELABAPDB116509835&prefLang=en_US |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c1f71eb049d04b088f4f63846e1ca06c |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 23146133 23146141 |
|---|